Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Human Pregnane X Receptor Antagonists and Agonists Define Molecular Requirements for Different Binding Sites

Sean Ekins, Cheng Chang, Sridhar Mani, Matthew D. Krasowski, Erica J. Reschly, Manisha Iyer, Vladyslav Kholodovych, Ni Ai, William J. Welsh, Michael Sinz, Peter W. Swaan, Rachana Patel and Kenneth Bachmann
Molecular Pharmacology September 2007, 72 (3) 592-603; DOI: https://doi.org/10.1124/mol.107.038398
Sean Ekins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheng Chang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sridhar Mani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew D. Krasowski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erica J. Reschly
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manisha Iyer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vladyslav Kholodovych
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ni Ai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William J. Welsh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Sinz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter W. Swaan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachana Patel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth Bachmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The pregnane X receptor (PXR) is an important transcriptional regulator of the expression of xenobiotic metabolism and transporter genes. The receptor is promiscuous, binding many structural classes of molecules that act as agonists at the ligand-binding domain, triggering up-regulation of genes, increasing the metabolism and excretion of therapeutic agents, and causing drug-drug interactions. It has been suggested that human PXR antagonists represent a means to counteract such interactions. Several azoles have been hypothesized to bind the activation function-2 (AF-2) surface on the exterior of PXR when agonists are concurrently bound in the ligand-binding domain. In the present study, we have derived novel computational models for PXR agonists using different series of imidazoles, steroids, and a set of diverse molecules with experimental PXR agonist binding data. We have additionally defined a novel pharmacophore for the steroidal agonist site. All agonist pharmacophores showed that hydrophobic features are predominant. In contrast, a qualitative comparison with the corresponding PXR antagonist pharmacophore models using azoles and biphenyls showed that they are smaller and hydrophobic with increased emphasis on hydrogen bonding features. Azole antagonists were docked into a proposed hydrophobic binding pocket on the outer surface at the AF-2 site and fitted comfortably, making interactions with key amino acids involved in charge clamping. Combining computational and experimental data for different classes of molecules provided strong evidence for agonists and antagonists binding distinct regions on PXR. These observations bear significant implications for future discovery of molecules that are more selective and potent antagonists.

Footnotes

  • M.D.K. is supported by grant K08-GM074238 from the National Institutes of Health and a Competitive Medical Research Fund grant from the University of Pittsburgh Medical Center. M.I. received support from a University of Pittsburgh Pathology Postdoctoral Research Training Program. S.M. was supported by the Damon Runyan Cancer Research Foundation (C1:15-02) N.A, V. K., and W.J.W. were supported by the United States Environmental Protection Agency-funded Environmental Bioinformatics and Computational Toxicology Center (ebCTC), under STAR Grant number GAD R 832721-010.

  • S.E., C.C., and S.M. contributed equally to this work.

  • Current affiliation: Pharmacokinetics, Dynamics, and Metabolism, Pfizer, Groton, CT.

  • Current affiliation: Sun Pharmaceutical Industries Inc., Bryan, Ohio.

  • Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

  • doi:10.1124/mol.107.038398.

  • ABBREVIATIONS: PXR, pregnane X receptor; LBD, ligand-binding domain; AF-2, activation function-2; LXR, liver X receptor; T-0901317, N-(2,2,2-trifluoroethyl)-N-{4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl}benzenesulfonamide; ET-743, trabectedin; SMRT, silencing mediator for retinoid and thyroid receptors; QSAR, quantitative structure-activity relationship; PLS, partial least-squares; L-742694, 2-((3,5-bis(trifluoromethyl)benzyl)oxy)-3-phenyl-4-((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine; CoMFA, comparative molecular field analysis; DMSO, dimethyl sulfoxide; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PRESS, predictive error sum of squares; CB, chlorobiphenyl; SR12813, [2-(3,5-di-tert-butyl-4-hydroxy-phenyl)-1-(diethoxy-phosphoryl)-vinyl]-phosphonic acid diethlyl ester.

  • ↵ Embedded Image The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.

    • Received May 22, 2007.
    • Accepted June 18, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 72 (3)
Molecular Pharmacology
Vol. 72, Issue 3
1 Sep 2007
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Human Pregnane X Receptor Antagonists and Agonists Define Molecular Requirements for Different Binding Sites
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Human Pregnane X Receptor Antagonists and Agonists Define Molecular Requirements for Different Binding Sites

Sean Ekins, Cheng Chang, Sridhar Mani, Matthew D. Krasowski, Erica J. Reschly, Manisha Iyer, Vladyslav Kholodovych, Ni Ai, William J. Welsh, Michael Sinz, Peter W. Swaan, Rachana Patel and Kenneth Bachmann
Molecular Pharmacology September 1, 2007, 72 (3) 592-603; DOI: https://doi.org/10.1124/mol.107.038398

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Human Pregnane X Receptor Antagonists and Agonists Define Molecular Requirements for Different Binding Sites

Sean Ekins, Cheng Chang, Sridhar Mani, Matthew D. Krasowski, Erica J. Reschly, Manisha Iyer, Vladyslav Kholodovych, Ni Ai, William J. Welsh, Michael Sinz, Peter W. Swaan, Rachana Patel and Kenneth Bachmann
Molecular Pharmacology September 1, 2007, 72 (3) 592-603; DOI: https://doi.org/10.1124/mol.107.038398
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Analgesic Effects and Mechanisms of Licochalcones
  • Induced Fit Ligand Binding to CYP3A4
  • Englerin A Inhibits T-Type Channels
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics